Vimentin as a target for the treatment of COVID-19.
Identifieur interne : 000268 ( Main/Exploration ); précédent : 000267; suivant : 000269Vimentin as a target for the treatment of COVID-19.
Auteurs : Zhenlin Li [France] ; Denise Paulin [France] ; Patrick Lacolley [France] ; Dario Coletti [France, Italie] ; Onnik Agbulut [France]Source :
- BMJ open respiratory research [ 2052-4439 ] ; 2020.
Descripteurs français
- KwdFr :
- Animaux (MeSH), Antiviraux (pharmacologie), Betacoronavirus (physiologie), Découverte de médicament (méthodes), Humains (MeSH), Infections à coronavirus (métabolisme), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Pandémies (MeSH), Pneumopathie infectieuse (immunologie), Pneumopathie infectieuse (métabolisme), Pneumopathie infectieuse (traitement médicamenteux), Pneumopathie virale (métabolisme), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Pénétration virale (effets des médicaments et des substances chimiques), Récepteurs viraux (MeSH), Régulation négative (MeSH), Réplication virale (physiologie), Souris (MeSH), Vimentine (physiologie).
- MESH :
- effets des médicaments et des substances chimiques : Pénétration virale.
- immunologie : Pneumopathie infectieuse.
- métabolisme : Infections à coronavirus, Pneumopathie infectieuse, Pneumopathie virale.
- méthodes : Découverte de médicament.
- pharmacologie : Antiviraux.
- physiologie : Betacoronavirus, Réplication virale, Vimentine.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie infectieuse, Pneumopathie virale.
- virologie : Infections à coronavirus, Pneumopathie virale.
- Animaux, Humains, Pandémies, Récepteurs viraux, Régulation négative, Souris.
English descriptors
- KwdEn :
- Animals (MeSH), Antiviral Agents (pharmacology), Betacoronavirus (physiology), Coronavirus Infections (drug therapy), Coronavirus Infections (metabolism), Coronavirus Infections (virology), Down-Regulation (MeSH), Drug Discovery (methods), Humans (MeSH), Mice (MeSH), Pandemics (MeSH), Pneumonia (drug therapy), Pneumonia (immunology), Pneumonia (metabolism), Pneumonia, Viral (drug therapy), Pneumonia, Viral (metabolism), Pneumonia, Viral (virology), Receptors, Virus (MeSH), Vimentin (physiology), Virus Internalization (drug effects), Virus Replication (physiology).
- MESH :
- chemical , pharmacology : Antiviral Agents.
- drug effects : Virus Internalization.
- drug therapy : Coronavirus Infections, Pneumonia, Pneumonia, Viral.
- immunology : Pneumonia.
- metabolism : Coronavirus Infections, Pneumonia, Pneumonia, Viral.
- methods : Drug Discovery.
- physiology : Betacoronavirus, Vimentin, Virus Replication.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Animals, Down-Regulation, Humans, Mice, Pandemics, Receptors, Virus.
Abstract
We and others propose vimentin as a possible cellular target for the treatment of COVID-19. This innovative idea is so recent that it requires further attention and debate. The significant role played by vimentin in virus-induced infection however is well established: (1) vimentin has been reported as a co-receptor and/or attachment site for SARS-CoV; (2) vimentin is involved in viral replication in cells; (3) vimentin plays a fundamental role in both the viral infection and the consequent explosive immune-inflammatory response and (4) a lower vimentin expression is associated with the inhibition of epithelial to mesenchymal transition and fibrosis. Moreover, the absence of vimentin in mice makes them resistant to lung injury. Since vimentin has a twofold role in the disease, not only being involved in the viral infection but also in the associated life-threatening lung inflammation, the use of vimentin-targeted drugs may offer a synergistic advantage as compared with other treatments not targeting vimentin. Consequently, we speculate here that drugs which decrease the expression of vimentin can be used for the treatment of patients with COVID-19 and advise that several Food and Drug Administration-approved drugs be immediately tested in clinical trials against SARS-CoV-2, thus broadening therapeutic options for this type of viral infection.
DOI: 10.1136/bmjresp-2020-000623
PubMed: 32913008
Affiliations:
- France, Italie
- Grand Est, Lorraine (région), Île-de-France
- Metz, Nancy, Paris
- Université de Lorraine
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vimentin as a target for the treatment of COVID-19.</title><author><name sortKey="Li, Zhenlin" sort="Li, Zhenlin" uniqKey="Li Z" first="Zhenlin" last="Li">Zhenlin Li</name><affiliation wicri:level="3"><nlm:affiliation>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Paulin, Denise" sort="Paulin, Denise" uniqKey="Paulin D" first="Denise" last="Paulin">Denise Paulin</name><affiliation wicri:level="3"><nlm:affiliation>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Lacolley, Patrick" sort="Lacolley, Patrick" uniqKey="Lacolley P" first="Patrick" last="Lacolley">Patrick Lacolley</name><affiliation wicri:level="4"><nlm:affiliation>Inserm, UMR_S 1116, DCAC, Université de Lorraine, Nancy, Lorraine, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm, UMR_S 1116, DCAC, Université de Lorraine, Nancy, Lorraine</wicri:regionArea><wicri:noRegion>Lorraine</wicri:noRegion><orgName type="university">Université de Lorraine</orgName><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Coletti, Dario" sort="Coletti, Dario" uniqKey="Coletti D" first="Dario" last="Coletti">Dario Coletti</name><affiliation wicri:level="3"><nlm:affiliation>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Anatomy, Histology, Forensic Medicine & Orthopedics, Histology & Medical Embryology Section, Sapienza University of Rome, Roma, Lazio, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Anatomy, Histology, Forensic Medicine & Orthopedics, Histology & Medical Embryology Section, Sapienza University of Rome, Roma, Lazio</wicri:regionArea><wicri:noRegion>Lazio</wicri:noRegion></affiliation></author><author><name sortKey="Agbulut, Onnik" sort="Agbulut, Onnik" uniqKey="Agbulut O" first="Onnik" last="Agbulut">Onnik Agbulut</name><affiliation wicri:level="3"><nlm:affiliation>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris, France onnik.agbulut@sorbonne-universite.fr.</nlm:affiliation><country wicri:rule="url">France</country><wicri:regionArea>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32913008</idno><idno type="pmid">32913008</idno><idno type="doi">10.1136/bmjresp-2020-000623</idno><idno type="wicri:Area/Main/Corpus">000165</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000165</idno><idno type="wicri:Area/Main/Curation">000165</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000165</idno><idno type="wicri:Area/Main/Exploration">000165</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Vimentin as a target for the treatment of COVID-19.</title><author><name sortKey="Li, Zhenlin" sort="Li, Zhenlin" uniqKey="Li Z" first="Zhenlin" last="Li">Zhenlin Li</name><affiliation wicri:level="3"><nlm:affiliation>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Paulin, Denise" sort="Paulin, Denise" uniqKey="Paulin D" first="Denise" last="Paulin">Denise Paulin</name><affiliation wicri:level="3"><nlm:affiliation>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Lacolley, Patrick" sort="Lacolley, Patrick" uniqKey="Lacolley P" first="Patrick" last="Lacolley">Patrick Lacolley</name><affiliation wicri:level="4"><nlm:affiliation>Inserm, UMR_S 1116, DCAC, Université de Lorraine, Nancy, Lorraine, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm, UMR_S 1116, DCAC, Université de Lorraine, Nancy, Lorraine</wicri:regionArea><wicri:noRegion>Lorraine</wicri:noRegion><orgName type="university">Université de Lorraine</orgName><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Coletti, Dario" sort="Coletti, Dario" uniqKey="Coletti D" first="Dario" last="Coletti">Dario Coletti</name><affiliation wicri:level="3"><nlm:affiliation>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Anatomy, Histology, Forensic Medicine & Orthopedics, Histology & Medical Embryology Section, Sapienza University of Rome, Roma, Lazio, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Anatomy, Histology, Forensic Medicine & Orthopedics, Histology & Medical Embryology Section, Sapienza University of Rome, Roma, Lazio</wicri:regionArea><wicri:noRegion>Lazio</wicri:noRegion></affiliation></author><author><name sortKey="Agbulut, Onnik" sort="Agbulut, Onnik" uniqKey="Agbulut O" first="Onnik" last="Agbulut">Onnik Agbulut</name><affiliation wicri:level="3"><nlm:affiliation>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris, France onnik.agbulut@sorbonne-universite.fr.</nlm:affiliation><country wicri:rule="url">France</country><wicri:regionArea>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">BMJ open respiratory research</title><idno type="eISSN">2052-4439</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Antiviral Agents (pharmacology)</term><term>Betacoronavirus (physiology)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (metabolism)</term><term>Coronavirus Infections (virology)</term><term>Down-Regulation (MeSH)</term><term>Drug Discovery (methods)</term><term>Humans (MeSH)</term><term>Mice (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia (drug therapy)</term><term>Pneumonia (immunology)</term><term>Pneumonia (metabolism)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (metabolism)</term><term>Pneumonia, Viral (virology)</term><term>Receptors, Virus (MeSH)</term><term>Vimentin (physiology)</term><term>Virus Internalization (drug effects)</term><term>Virus Replication (physiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Antiviraux (pharmacologie)</term><term>Betacoronavirus (physiologie)</term><term>Découverte de médicament (méthodes)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (métabolisme)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (virologie)</term><term>Pandémies (MeSH)</term><term>Pneumopathie infectieuse (immunologie)</term><term>Pneumopathie infectieuse (métabolisme)</term><term>Pneumopathie infectieuse (traitement médicamenteux)</term><term>Pneumopathie virale (métabolisme)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (virologie)</term><term>Pénétration virale (effets des médicaments et des substances chimiques)</term><term>Récepteurs viraux (MeSH)</term><term>Régulation négative (MeSH)</term><term>Réplication virale (physiologie)</term><term>Souris (MeSH)</term><term>Vimentine (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Virus Internalization</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Pénétration virale</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Pneumopathie infectieuse</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Pneumonia</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Discovery</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie infectieuse</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Découverte de médicament</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Betacoronavirus</term><term>Réplication virale</term><term>Vimentine</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Betacoronavirus</term><term>Vimentin</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie infectieuse</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Down-Regulation</term><term>Humans</term><term>Mice</term><term>Pandemics</term><term>Receptors, Virus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Pandémies</term><term>Récepteurs viraux</term><term>Régulation négative</term><term>Souris</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We and others propose vimentin as a possible cellular target for the treatment of COVID-19. This innovative idea is so recent that it requires further attention and debate. The significant role played by vimentin in virus-induced infection however is well established: (1) vimentin has been reported as a co-receptor and/or attachment site for SARS-CoV; (2) vimentin is involved in viral replication in cells; (3) vimentin plays a fundamental role in both the viral infection and the consequent explosive immune-inflammatory response and (4) a lower vimentin expression is associated with the inhibition of epithelial to mesenchymal transition and fibrosis. Moreover, the absence of vimentin in mice makes them resistant to lung injury. Since vimentin has a twofold role in the disease, not only being involved in the viral infection but also in the associated life-threatening lung inflammation, the use of vimentin-targeted drugs may offer a synergistic advantage as compared with other treatments not targeting vimentin. Consequently, we speculate here that drugs which decrease the expression of vimentin can be used for the treatment of patients with COVID-19 and advise that several Food and Drug Administration-approved drugs be immediately tested in clinical trials against SARS-CoV-2, thus broadening therapeutic options for this type of viral infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32913008</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2052-4439</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>09</Month></PubDate></JournalIssue><Title>BMJ open respiratory research</Title><ISOAbbreviation>BMJ Open Respir Res</ISOAbbreviation></Journal><ArticleTitle>Vimentin as a target for the treatment of COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000623</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjresp-2020-000623</ELocationID><Abstract><AbstractText>We and others propose vimentin as a possible cellular target for the treatment of COVID-19. This innovative idea is so recent that it requires further attention and debate. The significant role played by vimentin in virus-induced infection however is well established: (1) vimentin has been reported as a co-receptor and/or attachment site for SARS-CoV; (2) vimentin is involved in viral replication in cells; (3) vimentin plays a fundamental role in both the viral infection and the consequent explosive immune-inflammatory response and (4) a lower vimentin expression is associated with the inhibition of epithelial to mesenchymal transition and fibrosis. Moreover, the absence of vimentin in mice makes them resistant to lung injury. Since vimentin has a twofold role in the disease, not only being involved in the viral infection but also in the associated life-threatening lung inflammation, the use of vimentin-targeted drugs may offer a synergistic advantage as compared with other treatments not targeting vimentin. Consequently, we speculate here that drugs which decrease the expression of vimentin can be used for the treatment of patients with COVID-19 and advise that several Food and Drug Administration-approved drugs be immediately tested in clinical trials against SARS-CoV-2, thus broadening therapeutic options for this type of viral infection.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhenlin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paulin</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacolley</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Inserm, UMR_S 1116, DCAC, Université de Lorraine, Nancy, Lorraine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coletti</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Histology, Forensic Medicine & Orthopedics, Histology & Medical Embryology Section, Sapienza University of Rome, Roma, Lazio, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agbulut</LastName><ForeName>Onnik</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-1923-8871</Identifier><AffiliationInfo><Affiliation>Biological Adaptation and Ageing, CNRS UMR 8256, Inserm U1164, Sorbonne Université, Institut de Biologie Paris-Seine, Paris, France onnik.agbulut@sorbonne-universite.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open Respir Res</MedlineTA><NlmUniqueID>101638061</NlmUniqueID><ISSNLinking>2052-4439</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011991">Receptors, Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014746">Vimentin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="N">Pneumonia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011991" MajorTopicYN="N">Receptors, Virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014746" MajorTopicYN="N">Vimentin</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">ARDS</Keyword><Keyword MajorTopicYN="Y">pneumonia</Keyword><Keyword MajorTopicYN="Y">respiratory infection</Keyword><Keyword MajorTopicYN="Y">viral infection</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>08</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>11</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32913008</ArticleId><ArticleId IdType="pii">7/1/e000623</ArticleId><ArticleId IdType="doi">10.1136/bmjresp-2020-000623</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li><li>Italie</li></country><region><li>Grand Est</li><li>Lorraine (région)</li><li>Île-de-France</li></region><settlement><li>Metz</li><li>Nancy</li><li>Paris</li></settlement><orgName><li>Université de Lorraine</li></orgName></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Li, Zhenlin" sort="Li, Zhenlin" uniqKey="Li Z" first="Zhenlin" last="Li">Zhenlin Li</name></region><name sortKey="Agbulut, Onnik" sort="Agbulut, Onnik" uniqKey="Agbulut O" first="Onnik" last="Agbulut">Onnik Agbulut</name><name sortKey="Coletti, Dario" sort="Coletti, Dario" uniqKey="Coletti D" first="Dario" last="Coletti">Dario Coletti</name><name sortKey="Lacolley, Patrick" sort="Lacolley, Patrick" uniqKey="Lacolley P" first="Patrick" last="Lacolley">Patrick Lacolley</name><name sortKey="Paulin, Denise" sort="Paulin, Denise" uniqKey="Paulin D" first="Denise" last="Paulin">Denise Paulin</name></country><country name="Italie"><noRegion><name sortKey="Coletti, Dario" sort="Coletti, Dario" uniqKey="Coletti D" first="Dario" last="Coletti">Dario Coletti</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000268 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000268 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32913008
|texte= Vimentin as a target for the treatment of COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32913008" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |